Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;31(2):43-62.
doi: 10.1016/j.blre.2016.09.005. Epub 2016 Oct 8.

Selecting initial treatment of acute myeloid leukaemia in older adults

Nikolai A Podoltsev  1 , Maximilian Stahl  2 , Amer M Zeidan  3 , Steven D Gore  4
Affiliations
Review

Selecting initial treatment of acute myeloid leukaemia in older adults

Nikolai A Podoltsev et al. Blood Rev. 2017 Mar.

Abstract

More than half of the patients with acute myeloid leukaemia (AML) are older than 60years. The treatment outcomes in this group remain poor with a median overall survival of <1year. Selecting initial treatment for these patients involves an assessment of 'fitness' for induction chemotherapy. This is done based on patient and disease-related characteristics which help to estimate treatment-related mortality and chance of complete remission with induction chemotherapy. If the risk of treatment-related mortality is high and/or the likelihood of a patient achieving a complete remission is low, lower-intensity treatment (low-dose cytarabine, decitabine and azacitidine) should be discussed. As outcomes in both groups of patients remain poor, enrolment into clinical trials of novel agents with varying mechanisms of action should be considered for all older adults with AML. Novel agents in Phase III development include CPX-351, guadecitabine (SGI-110), quizartinib, crenolanib, sapacitabine, vosaroxin and volasertib.

Keywords: AML; Clinical trial; Induction chemotherapy; Older adults; Treatment.

PubMed Disclaimer

Publication types